...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib
【24h】

Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib

机译：三个标准的放射反应生存患者的肝细胞癌治疗lenvatinib

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim Lenvatinib (LEN) is a newly approved, multikinase inhibitor for treating unresectable hepatocellular carcinoma. In the present study, we investigated the impact of three different criteria for evaluating radiological objective response (OR) on overall survival in real‐world data. Methods Consent for LEN therapy was obtained from 51 patients from April 2018 to March 2019. A total of 40 patients who received a minimal cumulative duration of 4?weeks of LEN were included in the analysis. Enhanced computed tomography scan was performed at baseline and every 4–8?weeks after LEN administration. Overall survival and OR were assessed with three different evaluations, as follows: Response Evaluation Criteria in Solid Tumors 1.1, modified Response Evaluation Criteria in Solid Tumors, and Choi criteria. Results The average observation period for all participants after LEN introduction was 209.4?±?77.5?days. The Response Evaluation Criteria in Solid Tumors 1.1, modified Response Evaluation Criteria in Solid Tumors, and Choi criteria identified 10 of 40 (25.0%), 15 of 40 (37.5%), and 18of 40 (45.0%) patients with OR, respectively. The median overall survival in progressive disease evaluated by each criterion was 227?days. This result was significantly shorter than OR. Furthermore, the cumulative duration of LEN administration (150?days) represented a significant prognostic factor (HR 0.160. 95% CI 0.039–0.646, P ?=?0.001). Conclusion The Response Evaluation Criteria in Solid Tumors 1.1, modified Response Evaluation Criteria in Solid Tumors, and Choi criteria were useful therapeutic evaluation methods in LEN therapy for unresectable hepatocellular carcinoma. LEN's appropriate effect evaluation and management might lead to a better prognosis.
机译：目的Lenvatinib (LEN)是一个新近批准的,multikinase抑制剂治疗不可切除的肝细胞癌。我们研究了三种不同的影响评估标准辐射目标响应(或)对整体生存在现实世界数据。从2018年4月获得51例2019年3月。最小累积时间4 ?被包括在分析中。断层扫描基线和执行每一个4 - 8 ?生存和或与三个评估不同的评估,如下:响应评估标准在实体肿瘤1.1中,修改在实体肿瘤反应评估标准,崔标准。兰后时期所有的参与者介绍209.4 ?±77.5 ?。评估标准在实体肿瘤1.1中,修改在实体肿瘤反应评估标准,崔标准确定10 40 (25.0%),1540(37.5%),和18患者40例(45.0%),或者分别。进行性疾病评估每个标准227 ?天。比或短。LEN政府持续时间(在150 ?天)代表一个重要的预后因子(人力资源0.160. 结论响应评估标准1.1实体肿瘤,修改后的反应评价在实体肿瘤标准,崔标准LEN有用的疗效评价方法治疗不可切除的肝细胞癌。和管理可能会导致一个更好的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号